CD28 Antibody (JJ319): sc-19599
- CD28 Antibody (JJ319) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against rat cd28 transfected mouse A20JB lymphoma cell line
- recommended for detection of CD28 of mouse and rat origin by FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD28 Antibody (JJ319). These reagents are now offered in bundles with CD28 Antibody (JJ319) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD28 Antibody (JJ319) is a mouse monoclonal IgG1 antibody that detects CD28 in mouse and rat samples through flow cytometry (FCM) applications. CD28 plays a crucial role in T cell activation and survival, serving as a primary co-stimulatory receptor that enhances T cell responses upon engagement with its ligands, CD80 and CD86, found on antigen-presenting cells. This interaction is vital for the effective functioning of the immune system, as CD28 not only promotes T cell proliferation but also influences the production of cytokines, which are essential for orchestrating immune responses. The importance of CD28 is underscored by CD28′s ability to provide a necessary second signal that, when combined with T cell receptor (TCR) signaling, leads to full T cell activation. Furthermore, CD28 expression on resting T cells contrasts with CTLA-4 expression on activated T cells, highlighting CD28′s role in maintaining immune homeostasis and preventing autoimmunity. Anti-CD28 antibody (JJ319) is an invaluable tool for researchers studying T cell biology and the mechanisms of immune regulation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD28 Antibody (JJ319) References:
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. | Maher, J., et al. 2002. Nat Biotechnol. 20: 70-5. PMID: 11753365
- A transendocytosis perspective on the CD28/CTLA-4 pathway. | Soskic, B., et al. 2014. Adv Immunol. 124: 95-136. PMID: 25175774
- Unusual CD4+CD28- T Cells and Their Pathogenic Role in Chronic Inflammatory Disorders. | Lee, GH. and Lee, WW. 2016. Immune Netw. 16: 322-329. PMID: 28035207
- PD1 functions by inhibiting CD28-mediated co-stimulation. | O'Donnell, JS., et al. 2017. Clin Transl Immunology. 6: e138. PMID: 28690844
- CD28 enhances mitochondrial function. | Dempsey, LA. 2017. Nat Immunol. 18: 1189. PMID: 29044234
- Selective Costimulation Blockade With Antagonist Anti-CD28 Therapeutics in Transplantation. | Vanhove, B., et al. 2019. Transplantation. 103: 1783-1789. PMID: 30951014
- CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade. | Sundqvist, KG. 2021. Front Immunol. 12: 670864. PMID: 33968078
- Harnessing CD8+CD28- Regulatory T Cells as a Tool to Treat Autoimmune Disease. | Ceeraz, S., et al. 2021. Cells. 10: PMID: 34831195
- Human CARMIL2 deficiency underlies a broader immunological and clinical phenotype than CD28 deficiency. | Lévy, R., et al. 2023. J Exp Med. 220: PMID: 36515678
- c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. | Xiong, Y., et al. 2023. Nat Cancer. 4: 1001-1015. PMID: 37336986
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD28 Antibody (JJ319) | sc-19599 | 200 µg/ml | $322.00 | |||
CD28 Antibody (JJ319): m-IgG Fc BP-HRP Bundle | sc-536619 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD28 Antibody (JJ319): m-IgGκ BP-HRP Bundle | sc-533776 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD28 Antibody (JJ319): m-IgG1 BP-HRP Bundle | sc-544711 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD28 Antibody (JJ319) FITC | sc-19599 FITC | 200 µg/ml | $336.00 | |||
CD28 Antibody (JJ319) PE | sc-19599 PE | 200 µg/ml | $349.00 |